URGN UroGen Pharma Ltd.
Price Chart
Executive Summary
HC Wainwright & Co. upgraded URGN from Neutral to Buy on June 16, maintaining its $50 price target, which implies 67% upside from the current $29.96. The upgrade adds to a heavily bullish consensus: 12 of 14 analysts rate Buy-equivalent (5 Strong Buy, 7 Buy) and only 2 Hold, with no Sells. The mean target of $35 offers a more modest 17% upside, and HCW's $50 target is 39% above consensus mean and 19% above the highest existing target of $42. HCW's track record is below average — 43% accuracy on 4,605 calls with a 2.5% average return — limiting the upgrade's credibility. EPS estimates have improved sharply: the current fiscal year loss narrowed from -$1.17 to -$0.83 over 30 days, and next year's EPS rose from $0.92 to $1.45. However, an insider sold $300,000 on May 8, opposing the bullish signal, while short interest stands at an extreme 63.2%, suggesting heavy bearish positioning. Overall, the upgrade is consensus-aligned but from a low-accuracy firm, and the insider sale tempers conviction; the high short interest keeps the squeeze narrative alive.
Impact Score
Consensus & Targets
Consensus across 14 analysts: 5 Strong Buy, 7 Buy, 2 Hold, 0 Sell — equivalent to 85.7% Buy ratings. The direction is decisively bullish, making HCW's upgrade a catch-up move rather than a contrarian call.
Current price: $29.96. Mean target: $35 (17% upside). Median: $37.5 (25% upside). High: $42 (40% upside). Low: $18 (40% downside). HCW's $50 target is the highest on the street, 39% above the mean and 19% above the prior high — an outlier that reflects extreme optimism relative to peers.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-11 | HC Wainwright & Co. | maintain | Buy | $45.00 |
| 2026-05-07 | Oppenheimer | maintain | Outperform | $40.00 |
| 2026-03-31 | D. Boral Capital | maintain | Buy | $33.00 |
| 2026-03-02 | D. Boral Capital | maintain | Buy | — |
| 2026-01-23 | D. Boral Capital | maintain | Buy | $33.00 |
| 2026-01-05 | D. Boral Capital | maintain | Buy | $33.00 |
| 2025-10-27 | HC Wainwright & Co. | reiterate | Buy | $40.00 |
| 2025-10-27 | D. Boral Capital | maintain | Buy | $25.00 |
| 2025-10-03 | D. Boral Capital | maintain | Buy | $25.00 |
| 2025-08-19 | Piper Sandler | initiate | Overweight | $36.00 |
No upgrades or downgrades in the past 30 days. EPS revisions are positive: current-year loss improved from -$1.17 to -$0.83 over 30 days (2 up, 1 down revisions); next-year EPS rose from $0.92 to $1.45 (0 down revisions). Estimates are trending higher across both periods.
Firm Track Record — HC Wainwright & Co.
HC Wainwright & Co. accuracy: 43% on 4605 calls | avg return: 2.5%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Goldman Sachs | 100% | 2/2 | 217.9% | top tier |
| Scotiabank | 100% | 2/2 | 47.1% | top tier |
| Guggenheim | 75% | 3/4 | 119.6% | top tier |
| D. Boral Capital | 71% | 12/17 | 15.9% | top tier |
| Oppenheimer | 60% | 3/5 | 62.1% | above average |
| HC Wainwright & Co. | 50% | 10/20 | 22.3% | below average |
| EF Hutton | 0% | 0/5 | -15% | below average |
HC Wainwright has 43% accuracy on 4,605 calls with a 2.5% average return, placing them below average. Top-tier firms covering URGN include Goldman Sachs (100% on 2 calls, +218% avg return), Scotiabank (100% on 2, +47%), and Guggenheim (75% on 4, +120%). D. Boral Capital is also top-tier at 71% accuracy on 17 calls with 15.9% avg return. HCW's track record weakens the upgrade's significance.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1y | $1.45 | $0.25 — $3.10 | $433.3M | ↑0 ↓0 |
| 0y | $-0.83 | $-1.45 — $-0.26 | $261.1M | ↑1 ↓0 |
| 0q | $-0.24 | $-0.37 — $-0.15 | $61.6M | ↑1 ↓0 |
| +1q | $-0.06 | $-0.32 — $0.12 | $72.1M | ↑1 ↓0 |
Cross-Platform Signals
Insider Schoenberg Mark sold $300k on May 8 — a single sell that weakly opposes the upgrade. No congressional trades or institutional position changes reported. Short interest is extremely high at 63.2% of float, indicating heavy bearish positioning that could trigger a squeeze if the stock rallies. The insider sell and high short interest create conflicting signals: the upgrade aligns with rising estimates and bullish consensus, but the insider activity and short interest warrant caution.
Actionable Insight
The upgrade from a low-accuracy firm with no PT change is a marginal positive. Traders should watch for a short squeeze given 63% short interest, but the $300k insider sell tempers conviction. Focus on EPS revision momentum as the stronger catalyst.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
8-K
| $26.54 $26.60 | ▲ +0.23% | ▲ +0.92% | $27.25 (+2.68%) |
|
May 16, 2026
24d ago
|
ANALYST-UPGRADE
| $14.34 $13.24 | ▼ −7.67% | ▼ −6.83% | $27.25 (+90.03%) |
|
May 6, 2026
4w ago
|
Press Release
| $26.25 $26.59 | ▲ +1.30% | ▲ +1.63% | $27.25 (+3.81%) |
|
Apr 29, 2026
5w ago
|
Press Release
| $23.34 $23.83 | ▼ −2.10% | ▼ −1.08% | $27.25 (−16.75%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $21.39 $22.54 | ▲ +5.38% | ▲ +4.16% | $27.25 (+27.40%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $19.02 $18.82 | ▼ −1.05% | ▼ −0.14% | $27.25 (+43.27%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $19.02 $18.82 | ▼ −1.05% | ▼ −0.14% | $27.25 (+43.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access